Loading
A phase 2 trial of Epcoritamab, Lenalidomide, Ibrutinib in hodgkin lymphoma and non-hodgkin lymphoma, run by Genmab, active and no longer recruiting.
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma is a phase 2 interventional study registered as NCT05283720 by Genmab, with 264 participants enrolled, started 2022-06-14 and due to reach its primary completion in 2032-11. Interventions recorded: Epcoritamab, Lenalidomide, Ibrutinib, Rituximab, Cyclophosphamide. Conditions listed: Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
Shares Epcoritamab, Genmab, Prednisone, Rituximab.
Shares Epcoritamab, Genmab, Prednisone, Rituximab.
Shares Epcoritamab, Genmab, Lenalidomide, Prednisone.
Shares Epcoritamab, Genmab, Lenalidomide, Rituximab.
Shares Epcoritamab, Genmab, Prednisone, Rituximab.
Shares Epcoritamab, Genmab, Lenalidomide, Rituximab.
Shares Genmab, Lenalidomide, Prednisone, Rituximab.
Shares Epcoritamab, Genmab, T-cell engagers (bispecific).